Holley-Cotec is a multinational pharmaceutical company which cares about international community. We dedicates into clinical trials and drug development and opened up cooperation with outstanding global research center and CRO companies. There are many papers which related to DHA-PPQ efficacy published in world tropical academic journals. These data are from multi-center clinical projects between Holley-Cotec and Oxford University which arouse attention in academic research scenario.

The company has been testifying DHA-PPQ’s safety on adult, children, pregnant, trans-racial groups in which those trials were all based on strict protocols. The publications have been referred and quoted by academics quite often and the results are accepted by top professionals. That is the reason more and more countries adopted DUO-COTECXIN as the first line treatment for P.f malaria patients.